RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis.

Miller, Robert E

RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis. [electronic resource] - Molecular cancer therapeutics Jul 2008 - 2160-9 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1535-7163

10.1158/1535-7163.MCT-08-0046 doi


Animals
Antineoplastic Combined Chemotherapy Protocols--pharmacology
Apoptosis--drug effects
Bone Neoplasms--complications
Cell Line, Tumor
Cell Proliferation--drug effects
Docetaxel
Humans
Male
Mice
Mice, Nude
Osteolysis--complications
Osteoprotegerin--pharmacology
Prostatic Neoplasms--pathology
RANK Ligand--antagonists & inhibitors
Receptors, Fc
Survival Analysis
Taxoids--pharmacology
Tumor Burden--drug effects
Whole Body Imaging
Xenograft Model Antitumor Assays